Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

COLUMBUS, Ohio (WCMH) — Sarepta Therapeutics announced it is laying off nearly 500 employees this week, including 80 at its Easton location. According to a mass layoff notice filed with the s… ...

Sarepta Therapeutics announced a layoff of 493 employees, including 80 in Franklin County, amid restructuring efforts and criticism from the FDA.

Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.

Axsome Therapeutics AXSM has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ...

“The developer of the CNSide technology invested over $300 million in this core technology and after a year of detailed analysis and preparation by our team and key consultants, our enthusiasm ...

Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.

mRNA-based vaccines Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by Pfizer-BioNTech and Moderna Therapeutics (3–4). Now, ...